{"nctId":"NCT04055090","briefTitle":"Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy","startDateStruct":{"date":"2019-02-04","type":"ACTUAL"},"conditions":["Painful Diabetic Neuropathy","Diabetic Neuropathy, Painful"],"count":101,"armGroups":[{"label":"Subjects who received Engensis (VM202)","type":"EXPERIMENTAL","interventionNames":["Genetic: Long-Term Follow-Up of Patients who Received Engensis (VM202)"]},{"label":"Subjects who received Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Long-Term Follow-Up of Patients who Received Placebo"]}],"interventions":[{"name":"Long-Term Follow-Up of Patients who Received Engensis (VM202)","otherNames":[]},{"name":"Long-Term Follow-Up of Patients who Received Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Were randomized and dosed in the VMDN-003 study\n2. Received all intramuscular injections of study drug on Days 0, 14, 90, and 104 in the VMDN-003 study\n3. Were in follow-up for the VMDN-003 study or had completed Day 270 within the last 90 days prior to signing consent\n\nExclusion Criteria:\n\n1. Were using an investigational drug or treatment\n2. Were unable or unwilling to give informed consent","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Long-term Safety for Engensis Versus Placebo","description":"Long-term (6 months) safety in terms of the incidence of Treatment-emergent Adverse Events and Treatment-emergent Serious Adverse Events for Subjects who received Engensis or Placebo (in the prior VMDN-003 study)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"The Change in the Average 24-hour Pain Score From Baseline (Day 0 of Study VMDN-003) to Day 365 for Engensis Versus Placebo","description":"The Average 24-hour Pain Score was obtained from the Daily Pain and Sleep Interference Diary. The change in the Average 24-hour Pain Score was determined from baseline (Day 0 of Study VMDN-003) to the Day 365 visit. The Average 24-hour Pain Score is an 11-point numerical scale with scores from 0 (No Pain) to 10 (Worst Possible Pain).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.32","spread":"2.36"},{"groupId":"OG001","value":"-1.49","spread":"1.76"}]}]}]},{"type":"SECONDARY","title":"Change in the Average 24-hour Pain Score From Day 270 to Day 365 for Engensis Versus Placebo","description":"The Average 24-hour Pain Score is from the Daily Pain and Sleep Interference Diary. The change in the Average 24-hour Pain Score was determined for Day 270 to Day 365. The Average 24-hour Pain Score is an 11-point numerical scale with scores from 0 (No Pain) to 10 (Worst Possible Pain).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.26","spread":"1.525"},{"groupId":"OG001","value":"0.29","spread":"1.430"}]}]}]},{"type":"SECONDARY","title":"Patient's Global Impression of Change at the Day 365 Visit for Engensis Versus Placebo","description":"The Patient's Global Impression of Change was completed by subjects (self-administered) at the Day 365 visit. The subject evaluated how his/her overall status had changed since the start of the study using a 7-point Patient's Global Impression of Change questionnaire scale, where 1 = Very Much Improved, 2 = Much Improved, 3 = Minimally Improved, 4 = No Change, 5 = Minimally Worse, 6 = Much Worse, and 7 = Very Much Worse.\n\nThe Outcome Measure was the Patient's Global Impression of Change Categories of Scores as follows: 1 = Very Much Improved or Much Improved, 0 = Minimally Improved/Worsened or No Change, and -1 = Much Worse or Very Much Worse.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Subgroup Analysis of the Change in the Average 24-hour Pain Score From Baseline (Day 0 of Study VMDN-003) to Day 365 for Engensis Versus Placebo for Subjects Without Gabapentin and/or Pregabalin Use at Baseline","description":"The Average 24-hour Pain Score was obtained from the Daily Pain and Sleep Interference Diary and the change in the Average 24-hour Pain Score from baseline (Day 0 of Study VMDN-003) to the Day 365 follow-up was determined. The Average 24-hour Pain Score is an 11-point numerical scale with scores from 0 (No Pain) to 10 (Worst Possible Pain).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.30","spread":"0.352"},{"groupId":"OG001","value":"-0.82","spread":"0.470"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":65},"commonTop":["Arthralgia","Acute sinusitis","Bronchitis","Diverticulitis","Helicobacter infection"]}}}